Investigational drug · Phase 3
BGF MDI 320
Also called: BGF
Not approved by FDA. In 3 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Asthma, COPD (Chronic Obstructive Pulmonary Disease).
Phase 3Last checked: Nov 20, 2026Latest source record: Oct 2, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
3
1 still active
All registered trials
10
Any phase or sponsor naming "BGF MDI 320"
First trial start
2020
Dec 15, 2020
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "BGF MDI 320", any sponsor or status.
Conditions studied
As listed on its trial records.
- Asthma
- COPD (Chronic Obstructive Pulmonary Disease)
Approved drugs for the same conditions: Asthma · COPD · Respiratory
Largest trials
Live from ClinicalTrials.gov: studies naming "BGF MDI 320" as an intervention, largest first.
- Study to Assess the Efficacy and Safety of PT010 Relative to PT003 and PT009 in Subjects With Moderate to Very Severe COPD (Ethos)Pivotal-lookingCompleted
Pearl Therapeutics, Inc.Industry
NCT02465567 · 8,588 participants · Start Jun 30, 2015 · Primary completion Jul 26, 2019
Drug: BGF MDI 320/14.4/9.6 μg; GFF MDI 14.4/9.6 μg and 2 more · For: COPD
Sites: Andalusia, Alabama; Athens, Alabama; Birmingham, Alabama · 741 sites in all
- A Study Evaluating the Efficacy of Budesonide, Glycopyrronium and Formoterol Fumarate Metered Dosed Inhaler on Cardiopulmonary Outcomes in Chronic Obstructive Pulmonary DiseasePivotal-lookingRecruiting
AstraZenecaAstraZeneca (AZN)
NCT06283966 · 5,250 participants (planned) · Start Feb 21, 2024 · Primary completion Dec 3, 2027
Drug: BGF MDI 320/14.4/9.6 μg; GFF MDI 14.4/9.6 μg · For: COPD (Chronic Obstructive Pulmonary Disease)
Sites: Athens, Alabama; Cullman, Alabama; Fairhope, Alabama · 922 sites in all
- Study to Assess PT010 in Adult and Adolescent Participants With Inadequately Controlled Asthma (KALOS)Pivotal-lookingCompleted
AstraZenecaAstraZeneca (AZN)
NCT04609878 · 2,274 participants · Start Dec 15, 2020 · Primary completion Mar 21, 2025
Drug: BGF MDI 320/28.8/9.6 μg; BGF MDI 320/14.4/9.6 μg and 2 more · For: Asthma
Sites: Saraland, Alabama; Phoenix, Arizona; Sun City West, Arizona · 360 sites in all
- Study to Assess PT010 in Adult and Adolescent Participants With Inadequately Controlled Asthma (LOGOS)Pivotal-lookingCompleted
AstraZenecaAstraZeneca (AZN)
NCT04609904 · 2,187 participants · Start Mar 1, 2021 · Primary completion Mar 20, 2025
Drug: BGF MDI 320/28.8/9.6 μg; BGF MDI 320/14.4/9.6 μg and 2 more · For: Asthma
Sites: Chandler, Arizona; Tempe, Arizona; Tucson, Arizona · 317 sites in all
- A Randomized, Double-Blind, Parallel-Group, 24-Week, Chronic-Dosing, Multi-Center Study to Assess the Efficacy and Safety of PT010, PT003, and PT009 Compared With Symbicort® Turbuhaler® (Kronos)Pivotal-lookingCompleted
Pearl Therapeutics, Inc.Industry
NCT02497001 · 1,902 participants · Start Aug 10, 2015 · Primary completion Jan 5, 2018
Drug: BGF MDI 320/14.4/9.6 μg; GFF MDI (PT003) 14.4/9.6 μg and 2 more · For: COPD
Sites: Andalusia, Alabama; Jasper, Alabama; Peoria, Arizona · 190 sites in all
- Study to Assess the Safety and Tolerability of PT010, PT009 and PT003 in Subjects With Moderate to Very Severe Chronic Obstructive Pulmonary DiseasePivotal-lookingCompleted
Pearl Therapeutics, Inc.Industry
NCT02536508 · 627 participants · Start Aug 10, 2015 · Primary completion Sep 12, 2017
Drug: BGF MDI 320/14.4/9.6 μg; GFF MDI 14.4/9.6 μg and 1 more · For: COPD
Sites: Dothan, Alabama; Jasper, Alabama; Peoria, Arizona · 64 sites in all
- A Study to Assess the Safety of Budesonide/Glycopyrronium/Formoterol Fumarate With a Next-Generation Propellant in Participants With Moderate to Very Severe Chronic Obstructive Pulmonary DiseasePivotal-lookingCompleted
AstraZenecaAstraZeneca (AZN)
NCT05573464 · 559 participants · Start Sep 27, 2022 · Primary completion Mar 26, 2024
Drug: BGF MDI HFO 320/14.4/9.6 μg; BGF MDI HFA 320/14.4/9.6 μg · For: Chronic Obstructive Pulmonary Disease (COPD)
Sites: Phoenix, Arizona; Newport Beach, California; Miami, Florida · 91 sites in all
- A Study to Investigate the Effect on Lung Function of an Approved COPD Treatment (BGF, With HFA Propellant) Compared to BGF Formulated With a Next-Generation Propellant in Participants 40 to 80 Years of Age With COPDPivotal-lookingCompleted
AstraZenecaAstraZeneca (AZN)
NCT06075095 · 297 participants · Start Jan 11, 2024 · Primary completion Aug 12, 2025
Drug: BGF MDI HFO 320/14.4/9.6μg; BGF MDI HFA 320/14.4/9.6 μg and 1 more · For: COPD (Chronic Obstructive Pulmonary Disease)
Sites: Sheffield, Alabama; Clearwater, Florida; Gainesville, Florida · 87 sites in all
Pearl Therapeutics, Inc.Industry
NCT03075267 · 96 participants · Start Apr 17, 2017 · Primary completion Sep 5, 2017
Drug: PT010 (BGF MDI) 320/14.4/9.6 µg; PT010 (BGF MDI) 160/14.4/9.6 µg and 1 more · For: Chronic Obstructive Pulmonary Disease
Sites: Shanghai, China
- To Assess the Efficacy and Safety of PT010 Compared to PT009 in Subjects With Moderate to Very Severe Chronic Obstructive Pulmonary DiseasePivotal-lookingWithdrawn
Pearl Therapeutics, Inc.Industry
NCT03081247 · 0 participants · Start Apr 16, 2018 · Primary completion Dec 7, 2018
Drug: BGF 320/14.4/9.6 µg MDI; BFF 320/9.6 µg · For: Chronic Obstructive Pulmonary Disease
Newest research
PubMed records naming it or its code names, newest first.
- Real-world outcomes after ensifentrine initiation in patients receiving single-inhaler triple therapy for COPD: a propensity-matched multicenter study.
Nasrullah A, Saeed H, Touloumes N, et al. · Respir Med 2026
- Pharmacodynamic Equivalence and Safety of Budesonide/Glycopyrrolate/Formoterol Fumarate With a Next-Generation Propellant Versus Hydrofluoroalkane-134a Propellant: A Randomized Phase 3 Study in Chronic Obstructive Pulmonary Disease.
Camiolo M, Pandya H, Jassal M, et al. · Chronic Obstr Pulm Dis 2026
- HDFF-Net: A Hybrid Dual-Feature Fusion Network with Bidirectional Gated Fusion for Colposcopic Transformation Zone Classification, Evaluated under a Leakage-Audited Cluster-Level Protocol.
Shubhaker B, Raghavendra BS · J Imaging Inform Med 2026
- Segmenting scaffolds with ingrown bone in micro-CT images: considerations of evaluation metrics and loss functions.
Aboutaleb S, Haug N, Keni-McCray P, et al. · Med Biol Eng Comput 2026
- Real-World Effectiveness of Budesonide/Glycopyrronium/Formoterol (BGF) Fixed-Dose Combination in Patients with COPD (RECORD Study): A Prospective Observational Study.
Watz H, Watt M, Morris T, et al. · Int J Chron Obstruct Pulmon Dis 2026
- A prospective observational real-world study to assess the effectiveness and safety of single-inhaler triple therapy with glycopyrrolate/formoterol fumarate/budesonide in patients with uncontrolled asthma.
Thekkinkattil M, Katiyar S, Gopal B, et al. · J Asthma 2026
Also in development for Asthma
- CM512Phase 39 trials
Keymed Biosciences Co.Ltd · Chronic Rhinosinusitis With Nasal Polyposis, Chronic Spontaneous Urticaria (CSU), Asthma
- LunsekimigSAR443765Phase 39 trials
Sanofi · Asthma, Chronic Obstructive Pulmonary Disease, Chronic Rhinosinusitis With Nasal Polyps
- GSK5784283Phase 38 trials
GSK · Pulmonary Disease, Chronic Obstructive, Asthma, Nasal Polyps
- PF-07275315tilrekimigPhase 38 trials
Pfizer · Atopic Dermatitis, Asthma, Moderate to Severe Chronic Obstructive Pulmonary Disease
- MG-K10Humanized Monoclonal AntibodyPhase 36 trials
Shanghai Mabgeek Biotech.Co.Ltd · Dermatitis, Atopic, Chronic Urticaria, Idiopathic, Atopic Dermatitis
- SHR-1905Phase 36 trials
Guangdong Hengrui Pharmaceutical Co., Ltd · Asthma, Chronic Rhinosinusitis With Nasal Polyps, Moderate-to-severe Atopic Dermatitis
- TozorakimabMEDI3506Phase 36 trials
AstraZeneca · Chronic Obstructive Pulmonary Disease (COPD), Asthma, Viral Lung Infection and Acute Respiratory Failure
- TQC2731Phase 35 trials
Shanghai Chia Tai Tianqing Pharmaceutical Technology Development Co., Ltd. · Asthma, Chronic Obstructive Pulmonary Disease, Chronic Rhinosinusitis With Nasal Polyps (CRSwNP)
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do. More from AstraZeneca.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.